Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478244 · ClinicalTrials.gov registry record · NA
Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00478244: Clinical Trial NA study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT00478244 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00478244, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: In animal models, stem cells have been shown to home to the skin and repair the biochemical and structural abnormalities associated with recessive dystrophic epidermolysis bullosa (RDEB) (collagen 7 deficiency). PURPOSE: To determine the safety and effectiveness of stem cell infusion in the treatment of RDEB.
Primary Outcome
Number of patients with epidermolysis bullosa who had collagen type VII. Type VII collagen defects cause recessive dystrophic epidermolysis bullosa (RDEB), a blistering skin disorder often accompanied by epidermal cancers.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- DRUG busulfan
- PROCEDURE hematopoietic bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-08 |
| Phase | NA |
Why NCT00478244 stopped before completion
NCT00478244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00478244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00478244 about?
NCT00478244 is a clinical study titled "Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa". RATIONALE: In animal models, stem cells have been shown to home to the skin and repair the biochemical and structural abnormalities associated with recessive dystrophic epidermolysis bullosa (RDEB) (collagen 7 deficiency). PURPOSE: To determine the safety and effectiveness of stem cell infusion in ...
What is the current status of trial NCT00478244?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2007-04. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00478244?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), busulfan (DRUG), hematopoietic bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00478244?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00478244's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia